BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunoreactivity of p16 in anal cytology specimens: histologic correlation.

BACKGROUND: Cytology has been proposed as a potential screening tool in the evaluation of squamous anorectal disease in view of the morphologic similarities between anal and cervical squamous lesions.

Due to potential diagnostic pitfalls in anal cytology, p16 overexpression in these specimens was studied.

No cell immunoreactive for p16 was found in 15 cases (5 benign cases and 10 cases with either LSIL or HSIL).

The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively.

CONCLUSIONS: The presence of p16 immunoreactivity is a good predictor of dysplasia in anal specimens.

[MeSH-major] Anus Neoplasms / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Neoplasms, Squamous Cell / pathology

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2006 American Cancer Society.

(PMID = 16404747.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignancies of the anal margin and perianal skin.

Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.

Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.

Proper diagnosis requires a high index of suspicion on the part of the surgeon.

Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.

Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]

[Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]

[Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]

[Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]

[Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]

[Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]

[Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]

(PMID = 20436838.001).

[ISSN] 1530-9681

[Journal-full-title] Clinics in colon and rectal surgery

[ISO-abbreviation] Clin Colon Rectal Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2780245

[Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.

Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.

We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.

The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]

[Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]

[Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]

[Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]

[Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]

[Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]

[Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]

[Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]

[Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]

[Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]

[Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]

[Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]

[Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]

[Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]

[Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]

[Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]

[Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]

[Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]

[Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]

[Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]

[Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]

[Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]

[Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]

[Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]

[Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]

[Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]

(PMID = 17061043.001).

[ISSN] 0167-6806

[Journal-full-title] Breast cancer research and treatment

[ISO-abbreviation] Breast Cancer Res. Treat.

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] Netherlands

[Other-IDs] NLM/ PMC2092407

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of genes differentially expressed in benign versus malignant thyroid tumors.

PURPOSE: Although fine-needle aspiration biopsy is the most useful diagnostic tool in evaluating a thyroid nodule, preoperative diagnosis of thyroid nodules is frequently imprecise, with up to 30% of fine-needle aspiration biopsy cytology samples reported as "suspicious" or "indeterminate."

EXPERIMENTAL DESIGN: In an attempt to identify diagnostic markers for the preoperative distinction of these lesions, we chose to study by microarray analysis the eight different thyroid tumor subtypes that can present a diagnostic challenge to the clinician.

RESULTS: Our microarray-based analysis of 94 thyroid tumors identified 75 genes that are differentially expressed between benign and malignant tumor subtypes.

Of these, 33 were overexpressed and 42 were underexpressed in malignant compared with benign thyroid tumors.

CONCLUSIONS: Our results suggest that these 12 genes could be useful in the development of a panel of markers to differentiate benign from malignant tumors and thus serve as an important first step in solving the clinical problem associated with suspicious thyroid lesions.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Diseases.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]

[Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):56-63 [17943974.001]

[Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]

[Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]

[Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1693-9 [15753364.001]

[Cites] Anal Quant Cytol Histol. 2005 Apr;27(2):101-10 [15913203.001]

[Cites] Biochem J. 2005 Jul 1;389(Pt 1):91-7 [15713121.001]

[Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]

[Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1069-83 [16050784.001]

[Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]

[Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]

[Cites] Clin Cancer Res. 2006 Aug 1;12(15):4773-83 [16899629.001]

[Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]

[Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]

[Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]

[Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]

[Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]

[Cites] Thyroid. 2001 Mar;11(3):271-7 [11327619.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]

[Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]

[Cites] Cell Calcium. 2002 Jul;32(1):1-10 [12127057.001]

[Cites] J Comput Biol. 2002;9(3):505-11 [12162889.001]

[Cites] Cancer Res. 2002 Sep 15;62(18):5351-7 [12235006.001]

[Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]

[Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]

[Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]

[Cites] Pathol Oncol Res. 2002;8(4):231-40 [12579208.001]

[Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]

[Cites] Clin Cancer Res. 2003 May;9(5):1710-20 [12738725.001]

[Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]

[Cites] Carcinogenesis. 2003 Jul;24(7):1191-8 [12807722.001]

[Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]

[Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]

[Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]

[Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]

[Cites] Ann Surg. 2004 Oct;240(4):667-74; discussion 675-6 [15383794.001]

[Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]

[Cites] Biochem J. 1997 May 15;324 ( Pt 1):311-9 [9164872.001]

[Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]

[Cites] Genomics. 1998 Mar 15;48(3):377-80 [9545645.001]

[Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]

[Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]

[Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]

[Cites] Endokrynol Pol. 2006;57 Suppl A:18-25 [17091452.001]

[Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):1935-42 [17161346.001]

[Cites] Cancer Res. 1998 Sep 15;58(18):4193-8 [9751634.001]

(PMID = 18519760.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247-05; United States / NCI NIH HHS / CA / CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247; United States / NCI NIH HHS / CA / R01-CA107247-01A1; United States / NCI NIH HHS / CA / CA107247-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ NIHMS282977; NLM/ PMC3086681

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.

Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.

To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.

One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.

One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.

We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18301250.001).

[ISSN] 1533-4058

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tubulovillous adenoma of anal canal: a case report.

Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.

We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.

Examination revealed a 4 cm friable mass attached to the anus by a stalk.

The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.

We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.

[MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis

[MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]

[Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]

[Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]

(PMID = 16586552.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] China

[Other-IDs] NLM/ PMC4124358

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.

In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).

However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.

[MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

[MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]

[Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]

[Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]

[Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]

[Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]

[Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]

[Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]

[Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]

[Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]

[Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]

[Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]

[Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]

[Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]

[Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]

[Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]

[Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]

[Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]

[Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]

[Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]

[Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]

[Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]

[Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]

[Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]

[Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]

[Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]

[Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]

[Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]

[Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]

[Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]

[Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]

[Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]

[Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]

[Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]

[Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]

[Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]

[Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]

[Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]

[Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]

[Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]

[Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]

[Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]

[Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]

[Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]

[Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]

[Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]

[Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]

[Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]

[Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]

[Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]

[Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]

[Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]

(PMID = 19113831.001).

[ISSN] 1520-6882

[Journal-full-title] Analytical chemistry

[ISO-abbreviation] Anal. Chem.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin

[Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors.

In this paper, we describe axonal responses of mouse cortical neurons in a "neuron-benign" gradient-generator device based on an open chamber that can establish highly stable gradients of diffusible molecules for at least 6 h with negligible shear stress, and also allows the neurons to thrive for at least 2 weeks.

[MeSH-minor] Animals. Axons / drug effects. Axons / physiology. Cell Culture Techniques. Cell Tracking. Equipment Design. Female. Mice. Nerve Growth Factors / pharmacology. Neurogenesis. Pregnancy. Signal Transduction. Tumor Suppressor Proteins / pharmacology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuron. 1996 Aug;17(2):203-15 [8780645.001]

[Cites] J Neurosci Res. 1995 Dec;42(5):674-83 [8600300.001]

[Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]

[Cites] Mol Cell Neurosci. 1997;8(6):417-29 [9143559.001]

[Cites] Nature. 1997 Jul 17;388(6639):275-9 [9230436.001]

[Cites] Neuron. 1997 Sep;19(3):575-89 [9331350.001]

[Cites] Neuron. 1997 Dec;19(6):1211-24 [9427245.001]

[Cites] Development. 1997 Dec;124(24):5063-74 [9362464.001]

[Cites] Cell. 1999 Jun 25;97(7):821-4 [10399909.001]

[Cites] Curr Opin Neurobiol. 1999 Oct;9(5):603-15 [10508749.001]

[Cites] Anal Chem. 2005 Feb 1;77(3):833-9 [15679351.001]

[Cites] Lab Chip. 2005 Apr;5(4):401-6 [15791337.001]

[Cites] Lab Chip. 2005 Jun;5(6):611-8 [15915253.001]

[Cites] Exp Cell Res. 2005 Dec 10;311(2):307-16 [16263111.001]

[Cites] Nat Neurosci. 2006 Apr;9(4):511-8 [16520734.001]

[Cites] Dev Biol. 2006 Apr 1;292(1):13-24 [16476423.001]

[Cites] Biomed Microdevices. 2006 Jun;8(2):109-18 [16688570.001]

[Cites] Development. 2006 Jul;133(13):2487-95 [16763203.001]

[Cites] Lab Chip. 2007 Jun;7(6):763-9 [17538719.001]

[Cites] Langmuir. 2007 Oct 23;23(22):10910-2 [17910490.001]

[Cites] Lab Chip. 2008 Jan;8(1):34-57 [18094760.001]

[Cites] Lab Chip. 2008 Feb;8(2):227-37 [18231660.001]

[Cites] Nat Cell Biol. 2008 Jun;10(6):698-706 [18469807.001]

[Cites] Lab Chip. 2008 Aug;8(8):1292-9 [18651071.001]

[Cites] Lab Chip. 2008 Sep;8(9):1468-77 [18818801.001]

[Cites] Lab Chip. 2008 Sep;8(9):1507-15 [18818806.001]

[Cites] Lab Chip. 2010 Jan 7;10(1):116-22 [20024059.001]

[Cites] Cell. 2010 May 14;141(4):632-44 [20434207.001]

[Cites] J Comp Neurol. 2000 Jan 10;416(2):201-12 [10581466.001]

[Cites] Int J Dev Neurosci. 2000 Nov;18(7):643-51 [10978842.001]

[Cites] Nat Neurosci. 2001 Nov;4 Suppl:1169-76 [11687826.001]

[Cites] Neuron. 2001 Nov 20;32(4):605-17 [11719202.001]

[Cites] Prog Neurobiol. 2001 Dec;65(6):593-608 [11728645.001]

[Cites] J Neurobiol. 2002 Apr;51(1):9-23 [11920724.001]

[Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]

[Cites] Nat Biotechnol. 2002 Aug;20(8):826-30 [12091913.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12542-7 [12237407.001]

[Cites] Lab Chip. 2004 Oct;4(5):420-4 [15472724.001]

[Cites] Nature. 1988 Dec 22-29;336(6201):775-8 [3205306.001]

[Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]

[Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]

(PMID = 20957287.001).

[ISSN] 1757-9708

[Journal-full-title] Integrative biology : quantitative biosciences from nano to macro

[ISO-abbreviation] Integr Biol (Camb)

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / R01 NS064387

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1

[Other-IDs] NLM/ NIHMS513943; NLM/ PMC3786697

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation.

OBJECTIVE: To study the effect of Simotang oral liquid and glycerin enema on the patients' bowel sound (BS) restoration and anal exhaust after abdominal gynecological operation.

METHOD: Ninety patients with benign tumor who had undergone gynecological operation were randomly divided into the Simotang group, treated after operation with Simotang oral liquid; the enema group, treated with glycerin enema, and the control group, non-treated.

The restoration time of BS and anal exhaust were observed.

RESULTS: Compared with the control group, the restoration time of BS and anus exhaust were both significantly shorter in the Simotang group and the enema group, showing statistical significance (P < 0.05); but the difference between the two treated groups was insignificant (P > 0.05).

CONCLUSION: Simotang oral liquid and glycerine enema both could benefit the restoration of anal exhaust and BS after abdominal operation.

MedlinePlus Health Information. consumer health - After Surgery.

MedlinePlus Health Information. consumer health - Constipation.

MedlinePlus Health Information. consumer health - Uterine Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17005087.001).

[ISSN] 1672-0415

[Journal-full-title] Chinese journal of integrative medicine

[ISO-abbreviation] Chin J Integr Med

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] China

[Chemical-registry-number] 0 / Drugs, Chinese Herbal; PDC6A3C0OX / Glycerol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues.

FTIR and Raman spectroscopic studies of formalin-fixed normal, benign, and malignant ovarian tissues have been undertaken in order to investigate and attempt to understand the underlying biochemical changes associated with the disease, and to explore the feasibility of discriminating between these different tissue types.

Among the pathological tissues studied, spectra from benign tissues seem to contain more proteins and less DNA and lipids compared to malignant tissue spectra.

FTIR and Raman spectra of both normal and benign tissues showed more similarities than those of malignant tissues.

Cluster analysis of first-derivative Raman spectra in the 700-1700 cm(-1) range gave two clear groups, one corresponding to malignant and the other to normal+benign tissues.

At a lower heterogeneity level, the normal+benign cluster gave three nonoverlapping subclusters, one corresponding to normal and two for benign tissues.

Cluster analysis of second-derivative FTIR spectra in the combined spectral regions of 1540-1680 and 1720-1780 cm(-1) resulted into two clear clusters corresponding to malignant and normal+benign tissues.

The cluster corresponding to normal+benign tissues produced nonoverlapping subclusters for normal and benign tissues at a lower heterogeneity level.

The findings of this study demonstrate the feasibility of Raman and FTIR microspectroscopic discrimination of formalin-fixed normal, benign, and malignant ovarian tissues.

[MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods. Spectrum Analysis, Raman / methods

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17043798.001).

[ISSN] 1618-2642

[Journal-full-title] Analytical and bioanalytical chemistry

[ISO-abbreviation] Anal Bioanal Chem

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?

We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.

Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.

Histology did not confirm tumor recurrence.

The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.

Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.

It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).

[MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis

[MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

Genetic Alliance. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15966204.001).

[ISSN] 0172-6390

[Journal-full-title] Hepato-gastroenterology

[ISO-abbreviation] Hepatogastroenterology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Textural analysis in the diagnosis of benign and malignant breast cells.

OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.

The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.

RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.

Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18225392.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.

OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.

STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.

Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.

RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.

Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.

CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17879629.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.

OBJECTIVE: To investigate the expression of immunomodulating genes in prostate cancer and benign prostatic tissue.

STUDY DESIGN: We investigated by quantitative real-time polymerase chain reaction the expression of indoleamine 2,3-dioxygenase, arginase 1, arginase 2, inducible form of nitric oxide synthase, cyclooxygenase 2 (COX-2), programmed death ligand 1 and interleukin 10 in 36 matched pairs of samples from prostate cancer and benign prostatic tissue.

RESULTS: Among the genes analyzed, arginase 2 and COX-2 showed statistically significant up-regulation and down-regulation, respectively, in malignant compared to benign prostate tissue.

In addition, arginase 1 was more often present in cancer than benign samples.

We provide a snapshot of immunosuppressive gene expression at the transcriptional level in the prostate tumor microenvironment.

Genetic Alliance. consumer health - Prostate cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19402383.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / IL10 protein, human; 0 / Immunologic Factors; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 130068-27-8 / Interleukin-10; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.

OBJECTIVE: To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.

There was no correlation of VEGF-C to tumor stage, grading or the preoperative prostate-specific antigen values.

CONCLUSION: We cannot recommend VEGF-C serum level as a marker for tumor growth in PCa.

Genetic Alliance. consumer health - Prostate cancer.

Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18773737.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma.

OBJECTIVE: To assess how optical scatter properties in breast tissue, as measured by phase contrast microscopy and interpreted pathophysiologically, might be exploited as a diagnostic tool to differentiate cancer from benign tissue.

STUDY DESIGN: We evaluated frozen human breast tissue sections of adipose tissue, normal breast parenchyma, benign fibroadenoma tumors and noninvasive and invasive malignant cancers by phase contrast microscopy through quantification of grayscale values, using multiple regions of interest (ROI).

RESULTS: Stroma demonstrated significantly higher scatter intensity than did epithelium, with lower scattering in tumor-associated stroma as compared with normal or benign-associated stroma.

Measures were comparable for invasive and noninvasive malignant tumors but were higher than those found in benign tumors and were lowest in adipose tissue.

CONCLUSION: Significant differences were found in scatter coefficient properties of epithelium and stroma across diagnostic categories of breast tissue, particularly between benign and malignant-associated stroma.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]

[Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]

[Cites] Biophys J. 2002 Apr;82(4):2256-64 [11916880.001]

[Cites] Int J Cancer. 2003 May 20;105(1):53-60 [12672030.001]

[Cites] Cancer Res. 2003 Jul 1;63(13):3556-9 [12839941.001]

[Cites] Radiology. 2004 May;231(2):571-80 [15128998.001]

[Cites] Anal Quant Cytol Histol. 2004 Jun;26(3):166-74 [15218693.001]

[Cites] Phys Med Biol. 2004 Aug 21;49(16):3573-83 [15446788.001]

[Cites] Pathol Res Pract. 1984 Sep;179(1):61-6 [6504769.001]

[Cites] Surg Gynecol Obstet. 1987 Dec;165(6):523-9 [2825366.001]

[Cites] J Dermatol Surg Oncol. 1993 Sep;19(9):869-74 [7690052.001]

[Cites] Cancer Res. 2000 May 1;60(9):2497-503 [10811131.001]

[Cites] Radiology. 2000 Mar;214(3):895-901 [10715065.001]

[Cites] Am J Surg Pathol. 1995 Nov;19(11):1267-71 [7573688.001]

[Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]

[Cites] Opt Lett. 2007 Apr 15;32(8):933-5 [17375158.001]

[Cites] J Surg Oncol. 1997 Dec;66(4):248-53 [9425328.001]

[Cites] Ann Surg Oncol. 1998 Apr-May;5(3):220-6 [9607622.001]

[Cites] Phys Med Biol. 1998 Sep;43(9):2555-67 [9755945.001]

[Cites] Phys Med Biol. 1998 Oct;43(10):2845-52 [9814522.001]

[Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1122-8 [15568931.001]

[Cites] Biophys J. 2005 Apr;88(4):2929-38 [15653724.001]

[Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]

[Cites] Opt Lett. 2005 Jun 1;30(11):1354-6 [15981531.001]

[Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064007 [17212530.001]

[Cites] Histopathology. 2007 Feb;50(3):338-47 [17257129.001]

(PMID = 19736867.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U54 CA105480-010002; United States / NCI NIH HHS / CA / U54 CA105480; None / None / / U54 CA105480-010002; United States / NCI NIH HHS / CA / CA080139-09; United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P01 CA080139-09

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS183687; NLM/ PMC2857332

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.

Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.

Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.

However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.

These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYCLOPAMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]

[Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]

[Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]

[Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]

[Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]

[Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]

[Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]

[Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]

[Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]

[Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]

[Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]

[Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]

[Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]

[Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]

[Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]

[Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]

[Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]

[Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]

[Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]

[Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]

[Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]

[Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]

[Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]

[Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]

[Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]

[Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]

[Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]

[Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]

[Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]

[Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]

[Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]

[Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]

[Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]

[Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]

[Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]

[Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]

[Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]

[Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]

[Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]

[Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]

[Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]

[Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]

[Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]

[Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]

[Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]

(PMID = 16855373.001).

[ISSN] 1538-4047

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine

[Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.

Although this correlation means EZH2 could prove valuable as a biomarker in clinical settings, the question remains whether EZH2 is actually responsible for the initiation of these more aggressive tumor types.

In this study, EZH2-mediated neoplastic transformation of the normal prostate epithelial cell line benign prostate hyperplasia 1 (BPH1) was confirmed by in vivo tumor growth and in vitro colony formation.

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]

[Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]

[Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]

[Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]

[Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]

[Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]

[Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]

[Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]

[Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]

[Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]

[Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]

[Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]

[Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]

[Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]

[Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]

[Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]

[Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]

[Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]

[Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]

[Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]

[Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]

[Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]

[Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]

[Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]

[Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]

[Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]

[Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]

[Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]

[Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]

[Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]

[Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]

[Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]

[Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]

[Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]

[Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]

[Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]

[Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]

[Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]

[Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]

[Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]

[Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]

[Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]

[Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]

[Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]

[Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]

[Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]

[Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]

[Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]

[Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]

[Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]

[Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]

[Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]

[Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]

[Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]

[Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]

[Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]

[Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]

[Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]

[Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]

[Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]

(PMID = 19723877.001).

[ISSN] 1557-3125

[Journal-full-title] Molecular cancer research : MCR

[ISO-abbreviation] Mol. Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt

[Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

In this study, we developed a quantitative real-time PCR assay to assess the level of the DeltamtDNA(4977) mutation in tumor tissue samples from 55 primary breast cancer patients and 21 patients with benign breast disease (BBD).

The DeltamtDNA(4977) mutation levels were lower in tumor tissues than in adjacent normal tissues in both breast cancer and BBD subjects.

No significant difference between breast cancer and BBD patients was found in the DeltamtDNA(4977) mutation levels of tumor tissues and adjacent normal tissues.

The DeltamtDNA(4977) mutation levels were not significantly associated with clinicopathological characteristics (age, histology, tumor stage, and ER/PR status) in breast cancer or BBD patients.

Genetic Alliance. consumer health - Mitochondrial Disorders.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nucleic Acids Res. 2000 Jan 1;28(1):352-5 [10592272.001]

[Cites] Ai Zheng. 2004 Nov;23(11):1297-301 [15522177.001]

[Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]

[Cites] J Pathol. 2000 Jul;191(3):274-81 [10878549.001]

[Cites] Anal Biochem. 2000 Aug 15;284(1):70-6 [10933858.001]

[Cites] Mutat Res. 2001 Jun 27;493(1-2):67-74 [11516716.001]

[Cites] Nucleic Acids Res. 2002 Jan 1;30(1):158-62 [11752280.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Clin Chim Acta. 2002 Apr;318(1-2):33-40 [11880110.001]

[Cites] Nucleic Acids Res. 2002 Jul 15;30(14):e68 [12136116.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):7031-41 [12460924.001]

[Cites] Cancer Res. 2004 Feb 1;64(3):985-93 [14871829.001]

[Cites] Cancer Detect Prev. 2004;28(2):119-26 [15068836.001]

[Cites] Ann N Y Acad Sci. 2004 Apr;1011:154-67 [15126293.001]

[Cites] World J Gastroenterol. 2004 Jun 1;10(11):1560-4 [15162525.001]

[Cites] Carcinogenesis. 2005 Jan;26(1):145-52 [15375011.001]

[Cites] Genet Mol Res. 2004;3(3):395-409 [15614730.001]

[Cites] Cancer Biol Ther. 2004 Dec;3(12):1270-4 [15477759.001]

[Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):43-9 [15896297.001]

[Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]

[Cites] Int J Neuropsychopharmacol. 2005 Dec;8(4):515-22 [16202181.001]

[Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]

[Cites] BMC Cancer. 2006;6:93 [16620376.001]

[Cites] Br J Cancer. 2004 Jun 14;90(12):2390-6 [15150555.001]

[Cites] Anticancer Res. 2004 May-Jun;24(3a):1753-8 [15274351.001]

[Cites] Environ Mol Mutagen. 2004;44(4):313-20 [15476199.001]

[Cites] Nature. 1981 Apr 9;290(5806):457-65 [7219534.001]

[Cites] Cytogenet Cell Genet. 1995;71(1):99-103 [7606938.001]

[Cites] Eur J Biochem. 1998 Oct 1;257(1):192-201 [9799119.001]

[Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]

[Cites] Nat Genet. 1999 Oct;23(2):147 [10508508.001]

[Cites] Br J Haematol. 1999 Dec;107(4):861-9 [10606895.001]

(PMID = 17541740.001).

[ISSN] 0167-6806

[Journal-full-title] Breast cancer research and treatment

[ISO-abbreviation] Breast Cancer Res. Treat.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA064277; United States / NCI NIH HHS / CA / R01 CA 064277

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] Netherlands

[Chemical-registry-number] 0 / DNA, Mitochondrial

[Other-IDs] NLM/ NIHMS526435; NLM/ PMC3836503

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.

In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent prostate cancer cells PC-3 and the human benign prostate epithelial cells BPH-1.

These results show that doxazosin exerts its apoptotic effects against benign and malignant prostate cells via a death receptor-mediated mechanism with a potential integrin contribution towards cell survival outcomes.

MedlinePlus Health Information. consumer health - Prostate Cancer.

Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]

[Cites] Cell Death Differ. 2005 Mar;12(3):233-42 [15665818.001]

[Cites] Cell Tissue Res. 2000 Jul;301(1):153-62 [10928288.001]

[Cites] J Cell Biol. 2001 Feb 5;152(3):633-43 [11157988.001]

[Cites] J Urol. 2003 Mar;169(3):1150-6 [12576871.001]

[Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]

[Cites] Int J Cancer. 2003 Jul 10;105(5):593-600 [12740905.001]

[Cites] Oncogene. 2003 May 8;22(18):2795-804 [12743602.001]

[Cites] Br J Cancer. 2003 May 19;88(10):1615-21 [12771931.001]

[Cites] J Cell Physiol. 2003 Aug;196(2):386-93 [12811833.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]

[Cites] J Med Chem. 2004 Aug 26;47(18):4453-62 [15317457.001]

[Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]

[Cites] Cell. 1995 May 19;81(4):505-12 [7538907.001]

[Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]

[Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]

[Cites] Curr Biol. 1996 Oct 1;6(10):1241-3 [8939562.001]

[Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]

[Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]

[Cites] Br J Urol. 1997 Oct;80(4):521-32 [9352686.001]

[Cites] Cancer Res. 1998 Jan 1;58(1):76-83 [9426061.001]

[Cites] Prostate. 1998 Jul 1;36(2):92-101 [9655261.001]

[Cites] Cancer Res. 1998 Dec 15;58(24):5870-5 [9865748.001]

[Cites] Clin Cancer Res. 1997 Jun;3(6):963-72 [9815772.001]

[Cites] Cancer Res. 1999 Jan 15;59(2):382-90 [9927051.001]

[Cites] J Biol Chem. 1999 Mar 19;274(12):7987-92 [10075697.001]

[Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):603-7 [10080945.001]

[Cites] J Immunol. 1999 May 1;162(9):5205-11 [10227994.001]

[Cites] Cell Death Differ. 1999 May;6(5):394-401 [10381629.001]

[Cites] Br J Cancer. 1999 May;80(3-4):371-8 [10408840.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704 [10411938.001]

[Cites] Curr Biol. 1999 Sep 23;9(18):1043-6 [10508619.001]

[Cites] Curr Biol. 1999 Sep 23;9(18):1047-9 [10508612.001]

[Cites] Oncogene. 2001 Apr 5;20(15):1852-9 [11313933.001]

[Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]

[Cites] Cancer Res. 2002 Jan 15;62(2):597-602 [11809715.001]

[Cites] Prostate. 2002 Apr 1;51(1):42-9 [11920957.001]

[Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]

[Cites] Prostate. 2002 Jun 1;51(4):231-40 [11987151.001]

[Cites] Cancer. 2002 Jul 15;95(2):296-300 [12124829.001]

[Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):45-54 [10696460.001]

(PMID = 16397262.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA107575; United States / NCI NIH HHS / CA / R01 CA107575-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD95; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin

[Other-IDs] NLM/ NIHMS19062; NLM/ PMC1850148

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia.

The expression of AR in paired specimens of benign prostate and prostate cancer from 20 African and 20 Caucasian Americans was compared to demonstrate an application of this system.

RESULTS: The percent positive nuclei and percent nuclear area were similar by race in both benign prostate hyperplasia and prostate cancer.

Intensity of AR immunostaining was similar between races in benign prostate.

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] IEEE Trans Inf Technol Biomed. 1997 Jun;1(2):128-40 [11020815.001]

[Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]

[Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]

[Cites] J Cell Biochem Suppl. 2000;Suppl 35:151-7 [11389545.001]

[Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]

[Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]

[Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]

[Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]

[Cites] Cytometry A. 2003 Sep;55(1):30-42 [12938186.001]

[Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]

[Cites] Prostate. 2004 Jun 1;59(4):460-8 [15065095.001]

[Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]

[Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]

[Cites] Anal Quant Cytol Histol. 2004 Aug;26(4):194-200 [15457671.001]

[Cites] Cancer. 1980 Apr 15;45(7 Suppl):1929-36 [7370944.001]

[Cites] Prostate. 1982;3(4):321-32 [7122329.001]

[Cites] Cancer. 1992 Jan 15;69(2):511-9 [1728382.001]

[Cites] Urol Res. 1991;19(6):333-6 [1722053.001]

[Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]

[Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]

[Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]

[Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]

[Cites] Comput Methods Programs Biomed. 2000 Aug;63(1):55-70 [10927155.001]

[Cites] Annu Rev Biochem. 1994;63:451-86 [7979245.001]

[Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]

(PMID = 15888205.001).

[ISSN] 1475-925X

[Journal-full-title] Biomedical engineering online

[ISO-abbreviation] Biomed Eng Online

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739

[Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen

[Other-IDs] NLM/ PMC1145186

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.

As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.

Both of these benign tumors are known to be at risk of developing into cancer.

During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.

In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.

It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.

[MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood

Genetic Alliance. consumer health - Endometriosis.

MedlinePlus Health Information. consumer health - Endometriosis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17506483.001).

[ISSN] 0887-8013

[Journal-full-title] Journal of clinical laboratory analysis

[ISO-abbreviation] J. Clin. Lab. Anal.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Chromogranin A

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor feature visualization with unsupervised learning.

Dynamic contrast enhanced magnetic resonance imaging (DCE MRI) is applied for diagnosis and therapy control of breast cancer.

Computer-based diagnosis (CAD) systems have been proposed to analyze and classify signal time curve data, extracted from hand selected ROI in the DCE MRI data.

In this paper, we apply the self-organizing map (SOM) to a set of time curve feature vectors of single voxels from seven benign lesions and seven malignant tumors.

Using the trained SOM, we are able to identify voxels with benign or malignant signal characteristics and to visualize lesion cross-sections with pseudo-colors.

[MeSH-minor] Contrast Media. Diagnosis, Computer-Assisted. Female. Gadolinium DTPA. Humans

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - MRI Scans.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15907392.001).

[ISSN] 1361-8415

[Journal-full-title] Medical image analysis

[ISO-abbreviation] Med Image Anal

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.

OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.

STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.

The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.

The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.

By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18630841.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months.

Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n=140, P-value <0.0001).

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]

[Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]

[Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]

[Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]

[Cites] Carcinogenesis. 2007 Dec;28(12):2467-75 [17690110.001]

[Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):1-10 [10696454.001]

[Cites] Int J Cancer. 2000 May 20;89(3):230-5 [10861498.001]

[Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]

[Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]

[Cites] J Cell Physiol. 2001 Feb;186(2):153-68 [11169452.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]

[Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]

[Cites] J Cell Biochem. 2002;86(4):665-77 [12210733.001]

[Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]

[Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]

[Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]

[Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]

[Cites] Cancer. 2004 Sep 15;101(6):1345-56 [15316903.001]

[Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]

[Cites] J Urol. 1982 Oct;128(4):858-61 [7143620.001]

[Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]

[Cites] Nature. 1984 Jan 12-18;307(5947):131-6 [6318122.001]

[Cites] Endocrinology. 1990 Mar;126(3):1343-54 [2307108.001]

[Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):722-30 [2384450.001]

[Cites] Cell. 1991 Jan 25;64(2):231 [1846319.001]

[Cites] Acta Anat (Basel). 1992;143(2):139-50 [1598820.001]

[Cites] J Cell Sci. 1992 Jun;102 ( Pt 2):361-72 [1400638.001]

[Cites] Cancer. 1994 Aug 1;74(3 Suppl):1030-44 [8039137.001]

[Cites] Carcinogenesis. 1995 Jul;16(7):1499-503 [7614683.001]

[Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]

[Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]

[Cites] J Histochem Cytochem. 1998 Mar;46(3):379-88 [9487120.001]

[Cites] Cancer Res. 1998 Jun 15;58(12):2520-3 [9635571.001]

[Cites] Clin Cancer Res. 1998 Jul;4(7):1625-30 [9676836.001]

[Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]

[Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]

[Cites] Clin Cancer Res. 1996 Aug;2(8):1255-61 [9816295.001]

[Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]

[Cites] Genes Cells. 1998 Oct;3(10):659-70 [9893023.001]

[Cites] Mol Cancer. 2007;6:69 [17967179.001]

[Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]

[Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]

[Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]

[Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]

[Cites] Oncogene. 2006 May 4;25(19):2773-84 [16407846.001]

[Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]

[Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]

[Cites] Rev Endocr Metab Disord. 2006 Jun;7(1-2):41-9 [16944325.001]

[Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]

[Cites] Growth Factors. 1998;16(2):101-10 [9932228.001]

[Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]

[Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]

[Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]

(PMID = 18724388.001).

[ISSN] 1476-5594

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA108646; United States / NIGMS NIH HHS / GM / F31 GM079879; United States / PHS HHS / / FGM079879A; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / R01 CA108646-04; United States / NCI NIH HHS / CA / T32 CA009592; United States / NCI NIH HHS / CA / R01 CA108646; None / None / / R01 CA108646-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Ligands; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor

[Other-IDs] NLM/ NIHMS142310; NLM/ PMC3222150

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

OBJECTIVE: Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis.

Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.

Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines.

Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.

RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).

Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.

CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.

The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.

Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

Genetic Alliance. consumer health - Ovarian cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]

[Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]

[Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]

[Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]

[Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]

[Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]

[Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]

[Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]

[Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]

[Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]

[Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]

[Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]

[Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]

[Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]

[Cites] PLoS One. 2007;2(12):e1281 [18060075.001]

[Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]

[Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]

[Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]

[Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]

[Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]

[Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]

[Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]

[Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]

[Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]

[Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]

[Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]

[Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]

[Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]

[Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]

[Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]

[Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]

[Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]

[Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]

[Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]

[Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]

[Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]

[Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]

[Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]

[Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]

(PMID = 19647308.001).

[ISSN] 1095-6859

[Journal-full-title] Gynecologic oncology

[ISO-abbreviation] Gynecol. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G

[Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.

P16 is a tumor suppressor gene product, shown to be overexpressed in most cervical carcinomas and dysplasias associated with high-risk human papilloma virus (HPV) infection.

HPV is also associated with anal squamous dysplasias and carcinomas.

Significant interobserver and intraobserver variation exists in the interpretation of biopsies for anal intraepithelial neoplasia (AIN).

This study was undertaken to assess the potential role of p16 and Ki67 immunohistochemical expression in refining the diagnosis and grading of AIN.One-hundred and four anal biopsies from 74 patients were retrieved from the surgical pathology files of the department.

Conversely, absence of a p16 band of positivity coupled with Ki67 positivity in <50% of nuclei was frequently associated with benign lesions.

We conclude that when used together and evaluated in conjunction with H&E stained sections, p16 and Ki67 immunoexpression is a useful adjunct in the diagnosis and grading of AIN.

[MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ki-67 Antigen / metabolism. Papillomavirus Infections / pathology. Precancerous Conditions / pathology

[MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. DNA, Viral / analysis. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Papillomaviridae / genetics. Papillomaviridae / isolation & purification

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16819320.001).

[ISSN] 0147-5185

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Probing model tumor interfacial properties using piezoelectric cantilevers.

Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.

It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.

In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. Lead, elemental .

Hazardous Substances Data Bank. TITANIUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]

[Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]

[Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]

[Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]

[Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]

[Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]

[Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]

[Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]

[Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]

[Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]

[Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]

[Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]

[Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]

(PMID = 20887005.001).

[ISSN] 1089-7623

[Journal-full-title] The Review of scientific instruments

[ISO-abbreviation] Rev Sci Instrum

[Language] ENG

[Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium

[Other-IDs] NLM/ PMC2955722

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transanal endoscopic microsurgery (TEM) for rectal tumor: the first French single-center experience.

OBJECTIVE: Transanal endoscopic microsurgery (TEM) allows complete local excision of rectal tumor, especially in the middle and upper part of the rectum, and provides an alternative to conventional surgery.

This is a report of the first French single-center experience to assess the feasibility and postoperative results for rectal tumor excised by TEM.

The median distance from the anal verge was 60mm (range: 10-140).

CONCLUSION: TEM is a safe and effective procedure with low morbidity for local rectal tumor resection.

It allows local excision of benign tumors, especially those that are inaccessible to conventional local surgery resection, thereby avoiding radical surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.

(PMID = 20621428.001).

[ISSN] 0399-8320

[Journal-full-title] Gastroentérologie clinique et biologique

[ISO-abbreviation] Gastroenterol. Clin. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.

Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors.

Pituitary tumor-transforming gene (Pttg) deletion results in pituitary hypoplasia, low pituitary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.

As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Pttg(-/-)p21(-/-) relative to Rb(+/-)Pttg(-/-) pituitary glands, p21-dependent senescence provoked by Pttg deletion may underlie pituitary hypoplasia and decreased tumor development in Rb(+/-)Pttg(-/-) mice.

MedlinePlus Health Information. consumer health - Pituitary Tumors.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]

[Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]

[Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]

[Cites] Nature. 1998 Sep 10;395(6698):125-6 [9744268.001]

[Cites] EMBO J. 1999 Jan 4;18(1):22-7 [9878046.001]

[Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]

[Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]

[Cites] Mech Dev. 1999 Mar;81(1-2):23-35 [10330482.001]

[Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]

[Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]

[Cites] Mol Cell Biol. 1999 Oct;19(10):7011-9 [10490638.001]

[Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]

[Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]

[Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]

[Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]

[Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]

[Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]

[Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]

[Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]

[Cites] Cancer Cell. 2007 Jan;11(1):25-36 [17189716.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]

[Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]

[Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]

[Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]

[Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]

[Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]

[Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]

[Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]

[Cites] Curr Opin Cell Biol. 2001 Dec;13(6):748-53 [11698192.001]

[Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]

[Cites] Nat Cell Biol. 2000 Mar;2(3):148-55 [10707085.001]

[Cites] Pituitary. 1999 May;1(3-4):169-79 [11081195.001]

[Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]

[Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]

[Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9 [12124396.001]

[Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]

[Cites] Minerva Endocrinol. 2002 Dec;27(4):277-85 [12511850.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]

[Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]

[Cites] Cancer. 2003 Jun 1;97(11):2814-21 [12767095.001]

[Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]

[Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]

[Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]

[Cites] Oncogene. 2004 Mar 15;23(11):1998-2008 [15021887.001]

[Cites] Oncogene. 2004 Apr 22;23(19):3296-307 [15021915.001]

[Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]

[Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]

[Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]

[Cites] J Cell Biol. 1997 Jan 13;136(1):1-4 [9026502.001]

(PMID = 17975001.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA075979-09; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979; United States / NCI NIH HHS / CA / R01 CA075979-09

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Retinoblastoma Protein; 0 / Securin; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53

[Other-IDs] NLM/ NIHMS121885; NLM/ PMC2770267

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tailgut cyst initially misdiagnosed as ovarian tumor.

INTRODUCTION: Tailgut cyst (retrorectal cystic hamartoma) is an uncommon congenital lesion that arises from remnants of the embryonic post-anal gut.

It is usually benign and located in the retrorectal/presacral space.

The initial diagnosis was neoplasm of the right ovary.

Based on these histological findings, the final diagnosis was tailgut cyst.

CONCLUSION: Tailgut cyst is an uncommon entity that should be included in the differential diagnosis of retrorectal/presacral mass.

[MeSH-major] Cysts / diagnosis. Hamartoma / diagnosis. Peritoneal Neoplasms / diagnosis. Rectal Diseases / diagnosis

[MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16041543.001).

[ISSN] 0932-0067

[Journal-full-title] Archives of gynecology and obstetrics

[ISO-abbreviation] Arch. Gynecol. Obstet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.

With the use of seminal fluid samples representative of normal control, benign prostatic disease and prostate cancers, PAP and PSA were enriched by thiophilic absorption chromatography.

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]

[Cites] Clin Biochem. 2007 Mar;40(5-6):343-50 [17306785.001]

[Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):115-28 [17049937.001]

[Cites] Clin Cancer Res. 2007 Sep 1;13(17):5103-8 [17785564.001]

[Cites] Glycobiology. 2008 Jan;18(1):2-8 [17956937.001]

[Cites] J Proteome Res. 2008 Jan;7(1):367-74 [18047270.001]

[Cites] J Virol. 2008 Feb;82(3):1259-70 [18045939.001]

[Cites] Cancer Res. 2008 Feb 1;68(3):645-9 [18245462.001]

[Cites] J Mol Biol. 2008 Feb 29;376(4):1021-33 [18187150.001]

[Cites] Glycobiology. 2008 May;18(5):353-66 [18256178.001]

[Cites] Prostate. 2008 Jun 15;68(9):945-54 [18386289.001]

[Cites] Glycobiology. 2000 Feb;10(2):173-6 [10642608.001]

[Cites] Prostate. 2000 Feb 15;42(3):211-8 [10639192.001]

[Cites] Breast Cancer Res. 2000;2(5):321-3 [11250723.001]

[Cites] BJU Int. 2001 Mar;87(5):423-30 [11298030.001]

[Cites] Urology. 2001 Apr;57(4):707-11 [11306387.001]

[Cites] Biochim Biophys Acta. 2001 Feb 16;1525(1-2):149-60 [11342264.001]

[Cites] Hepatology. 2001 Jun;33(6):1488-95 [11391538.001]

[Cites] Proteomics. 2001 Jun;1(6):756-62 [11677781.001]

[Cites] Prostate. 2002 Feb 15;50(3):145-53 [11813206.001]

[Cites] Glycobiology. 2003 Jun;13(6):457-70 [12626390.001]

[Cites] J Am Soc Mass Spectrom. 2004 Mar;15(3):413-23 [14998545.001]

[Cites] Biochim Biophys Acta. 1985;780(2):119-50 [3890942.001]

[Cites] Science. 1987 May 1;236(4801):582-5 [2953071.001]

[Cites] N Engl J Med. 1987 Oct 8;317(15):909-16 [2442609.001]

[Cites] Clin Chem. 1993 Feb;39(2):181-95 [7679336.001]

[Cites] Protein Sci. 1993 Feb;2(2):183-96 [7680267.001]

[Cites] JAMA. 1995 Jan 25;273(4):289-94 [7529341.001]

[Cites] Prostate. 1995 Oct;27(4):187-97 [7479385.001]

[Cites] Anal Biochem. 1996 Sep 5;240(2):210-26 [8811911.001]

[Cites] Urology. 1996 Dec;48(6A Suppl):1-3 [8973692.001]

[Cites] J Chromatogr B Biomed Sci Appl. 1997 Aug 1;695(2):439-43 [9300882.001]

[Cites] J Int Fed Clin Chem. 1997 Sep;9(3):120-5 [10174623.001]

[Cites] J Urol. 1998 Mar;159(3):935-40 [9474187.001]

[Cites] J Urol. 2006 Dec;176(6 Pt 1):2383-5 [17085105.001]

(PMID = 19128049.001).

[ISSN] 1535-3893

[Journal-full-title] Journal of proteome research

[ISO-abbreviation] J. Proteome Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA085067-09; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / 2U01 CA98028; United States / NCI NIH HHS / CA / U01 CA085067-09

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Polysaccharides; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen

[Other-IDs] NLM/ NIHMS91585; NLM/ PMC2651839

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.

In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.

The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.

[MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis

[MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16770048.001).

[ISSN] 0910-6340

[Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry

[ISO-abbreviation] Anal Sci

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

[Chemical-registry-number] 0 / DNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.

METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.

RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.

CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]

[Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]

[Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]

[Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]

[Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]

[Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]

[Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]

[Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]

[Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]

[Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]

[Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]

[Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]

[Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]

[Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]

[Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]

[Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]

[Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]

[Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]

[Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]

[Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]

[Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]

[Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]

[Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]

[Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]

[Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]

[Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]

[Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]

[Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]

[Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]

[Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]

[Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]

[Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]

(PMID = 21278887.001).

[ISSN] 2005-0399

[Journal-full-title] Journal of gynecologic oncology

[ISO-abbreviation] J Gynecol Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC3026304

[Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Screening and expression of tumor markers in colorectal carcinoma].

OBJECTIVE: To screen the tumor markers of colorectal carcinoma and to investigate their expression in preoperative and postoperative serum.

METHODS: The distinct proteins in serum were detected in 87 cases of colorectal carcinoma, 68 cases of benign colorectal diseases and 56 healthy people by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).

Compared with benign colorectal diseases and healthy control, the expression of the two proteins was obviously up-regulated in colorectal carcinoma (P < 0.01).

CONCLUSIONS: Two proteins with mass-to-charge ratios of 5955 Da and 5972 Da could be regarded as tumor markers in colorectal carcinoma, the expression may has some regularity.

[MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Mass Screening / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17686301.001).

[ISSN] 0529-5815

[Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]

[ISO-abbreviation] Zhonghua Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Level set contouring for breast tumor in sonography.

The echogenicity, echotexture, shape, and contour of a lesion are revealed to be effective sonographic features for physicians to identify a tumor as either benign or malignant.

First, a sophisticated preprocessing filter reduces the noise, but preserves the shape and contrast of the breast tumor.

An adaptive initial contouring method is then performed to obtain an approximate circular contour of the tumor.

[MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Middle Aged

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biomed Tech (Berl). 2002;47 Suppl 1 Pt 2:633-5 [12465259.001]

[Cites] Radiology. 2003 Feb;226(2):504-14 [12563146.001]

[Cites] Neuroimage. 2004 Mar;21(3):1037-44 [15006671.001]

[Cites] Ultrasound Med Biol. 2004 May;30(5):625-32 [15183228.001]

[Cites] Med Image Anal. 2004 Sep;8(3):217-31 [15450217.001]

[Cites] Annu Rev Biomed Eng. 1999;1:559-88 [11701500.001]

[Cites] Med Phys. 2001 Aug;28(8):1652-9 [11548934.001]

[Cites] Ultrason Imaging. 2000 Oct;22(4):214-36 [11370905.001]

[Cites] Semin Ultrasound CT MR. 2000 Aug;21(4):308-16 [11014253.001]

[Cites] AJR Am J Roentgenol. 1998 Jan;170(1):109-14 [9423610.001]

[Cites] IEEE Trans Med Imaging. 2004 Apr;23(4):447-58 [15084070.001]

[Cites] Radiology. 1999 Nov;213(2):407-12 [10551220.001]

[Cites] Radiology. 1999 Dec;213(3):889-94 [10580971.001]

[Cites] Arch Surg. 2000 Jun;135(6):696-9 [10843366.001]

[Cites] Med Phys. 2000 Aug;27(8):1777-88 [10984224.001]

[Cites] Ultrasound Obstet Gynecol. 2005 Oct;26(5):558-66 [16086435.001]

[Cites] IEEE Trans Image Process. 2005 Jan;14(1):49-62 [15646872.001]

(PMID = 17252171.001).

[ISSN] 0897-1889

[Journal-full-title] Journal of digital imaging

[ISO-abbreviation] J Digit Imaging

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC3043893

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] p21(Cip1) restrains pituitary tumor growth.

As commonly encountered, pituitary adenomas are invariably benign.

Pituitary tumor transforming gene (Pttg) deletion results in pituitary p21 induction and abrogates tumor development in Rb(+/-)Pttg(-/-) mice. p21 disruption restores attenuated Rb(+/-)Pttg(-/-) pituitary proliferation rates and enables high penetrance of pituitary, but not thyroid, tumor growth in triple mutant animals (88% of Rb(+/-) and 72% of Rb(+/-)Pttg(-/-)p21(-/-) vs. 30% of Rb(+/-)Pttg(-/-) mice developed pituitary tumors, P < 0.001).

Intranuclear p21 accumulates in Pttg-null aneuploid GH-secreting cells, and GH(3) rat pituitary tumor cells overexpressing PTTG also exhibited increased levels of mRNA for both p21 (18-fold, P < 0.01) and ATM (9-fold, P < 0.01).

Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas.

MedlinePlus Health Information. consumer health - Pituitary Tumors.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]

[Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]

[Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]

[Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]

[Cites] Mod Pathol. 2001 Jan;14(1):20-8 [11211306.001]

[Cites] Nucleic Acids Res. 2001 Mar 15;29(6):1300-7 [11238996.001]

[Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]

[Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]

[Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]

[Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]

[Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]

[Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]

[Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]

[Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]

[Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]

[Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]

[Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]

[Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]

[Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]

[Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]

[Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]

[Cites] Oncogene. 1999 Sep 20;18(38):5293-303 [10498881.001]

[Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]

[Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]

[Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]

[Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]

[Cites] Mol Biol Cell. 2005 Oct;16(10):5013-25 [16030261.001]

[Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]

[Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]

[Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]

[Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]

[Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):220-30 [16932287.001]

[Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]

[Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]

[Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]

[Cites] Pituitary. 2009;12(1):40-50 [18270844.001]

[Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]

[Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]

[Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]

[Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]

[Cites] Cell. 2007 Oct 19;131(2):309-23 [17956732.001]

[Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]

[Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]

[Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]

[Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22 [11017877.001]

(PMID = 18981426.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Tumor Suppressor Proteins; 0 / pituitary tumor-transforming protein 1, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Vessel tortuosity and brain tumor malignancy: a blinded study.

Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.

The ability to detect and quantify tortuosity abnormalities on high-resolution magnetic resonance angiography (MRA) images offers a new approach to the noninvasive diagnosis of malignancy.

MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.

The operator performing the analysis was blinded to the diagnosis.

Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.

Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.

Tumors were identified as benign or malignant on the basis of histological evaluation.

RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.

CONCLUSIONS: Quantitative, statistical measures of vessel shape offer a new approach to the diagnosis and staging of disease.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]

[Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]

[Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]

[Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]

[Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]

[Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]

[Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]

[Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]

[Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]

[Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]

[Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]

[Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]

[Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]

[Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]

[Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]

[Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]

[Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]

[Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]

[Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]

(PMID = 16179200.001).

[ISSN] 1076-6332

[Journal-full-title] Academic radiology

[ISO-abbreviation] Acad Radiol

[Language] ENG

[Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07

[Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.

The anal sphincter function after 6 month of the ileoanal anastomosis remained good in 33/39 and acceptable in 6 cases, if the sphincter function was intact praeoperatively.

After the ultra low rectal resections all patients kept the normal anal shpincter function.

[MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17139887.001).

[ISSN] 0354-950X

[Journal-full-title] Acta chirurgica Iugoslavica

[ISO-abbreviation] Acta Chir Iugosl

[Language] eng

[Publication-type] Journal Article

[Publication-country] Serbia and Montenegro